 CONSHOHOCKEN, Pa., Dec. 18, 2022 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ: MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis NASH, plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022. 